Reports and Briefs on Therapy Area in China

Published within

« | 1 | 2 | 3 | 4 | » »|

Type Product title / description Pub Price
Report
Report

Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan

This report discusses four key Asian vaccines markets, India, China, South Korea and Taiwan. It analyzes the commercial and regulatory environment, guidelines, domestic and multinational competition as well as current and future indications.

Published By Datamonitor
02 Nov 2009 $3800
Buy
Report
Report

Stakeholder Opinions: Gene Therapy - Gene therapy to deliver after 20 years of clinical development

Comprehensive analysis of the gene therapy clinical pipeline across all geographic and therapeutic markets, with key opinion leader insights. Identification of drivers and inhibitors to the commercial success of gene therapy.

Published By Datamonitor
10 Dec 2009 $3800
Buy
Report
Report

Stakeholder Insight: Hepatitis B & C in Asia - Tapping the opportunity of high prevalence rates in China, Taiwan, South Korea and Turkey

China, Taiwan, South Korea and Turkey represent highly endemic areas for viral Hepatitis, but little is known about therapy dynamics and drivers of treatment choice. Particularly in China, a high emphasis on efficacy as well as cost leads to continued use of inexpensive, but suboptimal treatment approaches. For this report, 180 high-prescribing physicians where surveyed in these countries, providing a breakdown of patients numbers, frequently prescribed regimens and brand perceptions.

Published By Datamonitor
15 Feb 2010 $15200
Buy
Report
Report

Stakeholder Opinions: Sexual Dysfunction - The quest for the new Viagra continues

Examination of the key issues in the treatment of sexual dysfunction, including risk factors, estimates of patient potential, overview of current and pipeline treatments, unmet needs, analysis of commercial opportunities and key stakeholder opinions.

Published By Datamonitor
04 Mar 2010 $7600
Buy
Report
Report

Commercial Insight: Osteoporosis - Market players maximize revenue growth before the next challenging phase

Comprehensive analysis of the current and future osteoporosis drug market, with country-specific forecasts to 2019 of marketed, generic, and key pipeline drugs in the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK).

Published By Datamonitor
21 Jul 2010 $15200
Buy
Report
Report

Pharmaceutical M&A in the Asia-Pacific Region - India and China drive regional activity but Japan still dominates high value transactions

An overview of merger and acquisition (M&A) trends in developed and emerging pharmaceutical markets in the Asia-Pacific region from Q1 2007 to Q1 2010, with discussion of the drivers of recent deals and analysis of key M&As in individual countries.

Published By Datamonitor
19 Aug 2010 $7600
Buy
Report
Report

Stakeholder Insight: COPD in Emerging Markets (Brazil, India, China, US) - Key differences in treatment despite standardized guidelines

Datamonitor's survey of 300 respiratory experts in Brazil, India, China and the US addresses increased interest in COPD in the emerging markets. The US is included as a benchmark, providing unique insight and comparisons of COPD market dynamics.

Published By Datamonitor
22 Dec 2010 $15200
Buy
Report
Report

Commercial Insight: Hepatitis B in China

Discussion of the Chinese hepatitis B market including epidemiology, market drivers, and strategic analysis of key players. Assessment of marketed and pipeline products. Commercial forecast of market size and product sales and volumes to 2019.

Published By Datamonitor
17 Feb 2011 $5700
Buy
Report
Report

Commercial Insight: Antidiabetics in China - Rising patient numbers and novel products drive the future market

Discussion of the Chinese diabetes market including epidemiology, market drivers, and strategic analysis of key players. Assessment of marketed and pipeline products. Commercial forecast of market size and product sales and volumes to 2019.

Published By Datamonitor
21 Feb 2011 $5700
Buy
Report
Report

Epidemiology: Hepatitis B in China - Hepatitis B will continue to remain a public health burden in China, despite a a projected decrease in prevalent cases

Overview of hepatitis B definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10 year prevalent forecast and key patient segments across an emerging market.

Published By Datamonitor
12 Mar 2011 $5700
Buy

« | 1 | 2 | 3 | 4 | » »|

No help is available.